Stock Scorecard
Stock Summary for Immatics N.V (IMTX) - $10.42 as of 10/31/2025 3:11:24 PM EST
Total Score
13 out of 30
Safety Score
26 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IMTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IMTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IMTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for IMTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for IMTX (26 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for IMTX
Financial Details for IMTX
Company Overview |
|
|---|---|
| Ticker | IMTX |
| Company Name | Immatics N.V |
| Country | USA |
| Description | Immatics NV is a pioneering clinical-stage biopharmaceutical firm based in Tübingen, Germany, focused on advancing T-cell receptor (TCR) based immunotherapies for cancer treatment. Harnessing its proprietary platform, the company identifies and targets unique cancer-specific antigens, which may significantly improve immune responses against tumors. With a robust pipeline of innovative therapeutics, Immatics is strategically positioned to meet critical unmet needs in oncology, representing a compelling investment opportunity for institutional investors seeking exposure to transformative cancer therapies. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/18/2025 |
Stock Price History |
|
| Last Day Price | 10.42 |
| Price 4 Years Ago | 13.44 |
| Last Day Price Updated | 10/31/2025 3:11:24 PM EST |
| Last Day Volume | 582,179 |
| Average Daily Volume | 962,151 |
| 52-Week High | 11.25 |
| 52-Week Low | 3.30 |
| Last Price to 52 Week Low | 215.76% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.87 |
| Sector PE | 106.79 |
| 5-Year Average PE | 5.98 |
| Free Cash Flow Ratio | 4.94 |
| Industry Free Cash Flow Ratio | 14.55 |
| Sector Free Cash Flow Ratio | 28.77 |
| Current Ratio Most Recent Quarter | 8.80 |
| Total Cash Per Share | 2.11 |
| Book Value Per Share Most Recent Quarter | 3.82 |
| Price to Book Ratio | 1.95 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.17 |
| Price to Sales Ratio Twelve Trailing Months | 9.73 |
| Industry Price to Sales Ratio Twelve Trailing Months | 32.76 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.57 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 121,560,000 |
| Market Capitalization | 1,266,655,200 |
| Institutional Ownership | 77.41% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 115.69% |
| Reported EPS 12 Trailing Months | -0.66 |
| Reported EPS Past Year | -0.95 |
| Reported EPS Prior Year | 0.17 |
| Net Income Twelve Trailing Months | -73,910,000 |
| Net Income Past Year | 15,218,000 |
| Net Income Prior Year | -96,994,000 |
| Quarterly Revenue Growth YOY | -74.70% |
| 5-Year Revenue Growth | 53.23% |
| Operating Margin Twelve Trailing Months | -1,122.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 256,635,000 |
| Total Cash Past Year | 236,748,000 |
| Total Cash Prior Year | 218,472,000 |
| Net Cash Position Most Recent Quarter | 256,635,000 |
| Net Cash Position Past Year | 236,748,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 574,842,000 |
| Total Stockholder Equity Prior Year | 225,084,000 |
| Total Stockholder Equity Most Recent Quarter | 464,574,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -174,694,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.44 |
| Free Cash Flow Past Year | -174,510,000 |
| Free Cash Flow Prior Year | -12,729,000 |
Options |
|
| Put/Call Ratio | 0.40 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.71 |
| MACD Signal | 0.85 |
| 20-Day Bollinger Lower Band | 3.50 |
| 20-Day Bollinger Middle Band | 7.09 |
| 20-Day Bollinger Upper Band | 10.68 |
| Beta | 1.22 |
| RSI | 59.75 |
| 50-Day SMA | 6.15 |
| 150-Day SMA | 9.02 |
| 200-Day SMA | 9.18 |
System |
|
| Modified | 11/1/2025 1:42:34 AM EST |